Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BeiGene gets rights to Leap's DKN01 in Asia Pacific region

Executive Summary

Leap Therapeutics Inc. granted BeiGene Ltd. an exclusive option to license development and commercialization rights to DKN01, a Phase II anti-Dickkopf-1 (DKK1) antibody for gastric cancer, in Asia (excluding Japan), Australia, and New Zealand.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies

UsernamePublicRestriction

Register